PharmaCyte Biotech, Inc.
PMCBNASDAQHealthcare● Active
$0.70
+$0.00(+0.00%)
Market Cap$4757046
P/E Ratio—
52W High$1.51
52W Low$0.63
PharmaCyte Biotech, Inc. (PMCB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PMCB · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2026Report Date: Mar 17, 2026EPS Actual
$0.13
Est. -$0.06 · +316.7%
Revenue
—
Fiscal Period
Q1 FY2026
FY ends December
Report Date
Mar 17, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
PMCB reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 1, 2026 | -$0.06 | — | — | — | — | — |
| ▲ Q1 FY2026 | Mar 17, 2026 | -$0.06 | $0.13 | +316.7% | — | — | — |
| — Q4 FY2025 | Dec 18, 2025 | — | -$0.32 | — | — | — | — |
| — Q3 FY2025 | Sep 15, 2025 | — | -$0.09 | — | — | — | — |
| — Q3 FY2025 | Aug 11, 2025 | — | $1.73 | — | — | — | — |
| — Q1 FY2025 | Mar 17, 2025 | — | -$0.10 | — | — | — | — |
| — Q4 FY2024 | Dec 13, 2024 | — | -$0.29 | — | — | — | — |
| — Q3 FY2024 | Sep 16, 2024 | — | $0.14 | — | — | — | — |
Q3 FY2026
Jul 1, 2026
EPS Actual
—
EPS Est.
-$0.06
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 17, 2026Beat
EPS Actual
$0.13
EPS Est.
-$0.06
EPS Surpr.
+316.7%
Revenue
—
Q4 FY2025
Dec 18, 2025
EPS Actual
-$0.32
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Sep 15, 2025
EPS Actual
-$0.09
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 11, 2025
EPS Actual
$1.73
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 17, 2025
EPS Actual
-$0.10
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2024
Dec 13, 2024
EPS Actual
-$0.29
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Sep 16, 2024
EPS Actual
$0.14
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $-0.09 | $-0.09 | $-0.09 | 1 |
| Q4 FY2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q3 FY2027 | $-0.08 | $-0.08 | $-0.08 | 1 |
| Q2 FY2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q1 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q4 FY2026 | $-0.05 | $-0.05 | $-0.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2026 | Mar 17, 2026 | +316.7% | $0.70 | $0.69 | -1.57% |
| — Q4 FY2025 | Dec 18, 2025 | — | $0.82 | $0.84 | +1.85% |
| — Q3 FY2025 | Sep 15, 2025 | — | $1.04 | $1.03 | -0.96% |
| — Q3 FY2025 | Aug 11, 2025 | — | $0.83 | $0.88 | +5.53% |
| — Q1 FY2025 | Mar 17, 2025 | — | $1.58 | $1.58 | +0.00% |
| — Q4 FY2024 | Dec 13, 2024 | — | $1.67 | $1.72 | +2.99% |
| — Q3 FY2024 | Sep 16, 2024 | — | $1.90 | $1.91 | +0.53% |
| — Q3 FY2024 | Aug 13, 2024 | — | $1.85 | $1.85 | +0.00% |
Q1 FY2026-1.57%
Report Date
Mar 17, 2026
EPS Beat/Miss
+316.7%
Price Before
$0.70
Price After
$0.69
Q4 FY2025+1.85%
Report Date
Dec 18, 2025
EPS Beat/Miss
—
Price Before
$0.82
Price After
$0.84
Q3 FY2025-0.96%
Report Date
Sep 15, 2025
EPS Beat/Miss
—
Price Before
$1.04
Price After
$1.03
Q3 FY2025+5.53%
Report Date
Aug 11, 2025
EPS Beat/Miss
—
Price Before
$0.83
Price After
$0.88
Q1 FY2025+0.00%
Report Date
Mar 17, 2025
EPS Beat/Miss
—
Price Before
$1.58
Price After
$1.58
Q4 FY2024+2.99%
Report Date
Dec 13, 2024
EPS Beat/Miss
—
Price Before
$1.67
Price After
$1.72
Q3 FY2024+0.53%
Report Date
Sep 16, 2024
EPS Beat/Miss
—
Price Before
$1.90
Price After
$1.91
Q3 FY2024+0.00%
Report Date
Aug 13, 2024
EPS Beat/Miss
—
Price Before
$1.85
Price After
$1.85
Avg Beat Reaction-1.57%
Beat Rate1 / 8 quarters
Largest Move+5.53% (Q3 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PMCB ends December
PharmaCyte Biotech, Inc. (PMCB) most recently reported earnings on March 17, 2026 for Q1 FY2026, posting EPS of $0.13 — beating the analyst consensus of $-0.06 by +316.7%. The next PMCB earnings date is expected around September 1, 2026.
Each quarter, investors track PMCB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PMCB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PMCB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PMCB earnings · 5 questionsPharmaCyte Biotech, Inc.'s next earnings report is expected around September 1, 2026. PMCB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PMCB historically reports after market close (AMC).
PMCB earnings datewhen is PMCB earningsPMCB next earnings datewhen does PMCB report earningsPMCB earnings calendar
▸ Source: FMP · PharmaCyte Biotech, Inc. SEC filings · US GAAP · PharmaCyte Biotech, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026